Johnson & Johnson (NYSE: JNJ) Q2 2025 Earnings | 07/16/2025

About this video

Video by Inside TickerJohnson & Johnson (NYSE: JNJ) reported its Q2 2025 results on July 16, 2025, posting robust sales growth and surpassing both earnings and revenue expectations. Quarterly reported sales climbed 5.8% year-over-year to $23.74 billion, driven by strong performances in both the Innovative Medicine and MedTech segments. Net earnings rose to $5.54 billion, up 18.2% from the same period in 2024, while diluted earnings per share (EPS) increased to $2.29 from $1.93—a surge of 18.7%. On an adjusted basis, diluted EPS reached $2.77, slightly lower than last year's $2.82 but beating consensus estimates. Free cash flow for the year-to-date period was about $6.2 billion. The Innovative Medicine division generated $15.2 billion in revenue, a 4.9% increase largely fueled by robust oncology sales—especially for Darzalex and new launches despite some headwinds from biosimilar competition. The MedTech segment saw even stronger growth, up 7.3% to $8.54 billion, reflecting continued momentum in digital surgery, electrophysiology, and orthopedics. Regionally, U.S. sales led with an increase of 7.8%, while international sales rose 3.2%. Notably, the company cited several regulatory and clinical achievements, including FDA approval of IMAAVY for generalized myasthenia gravis and key data updates for pipeline assets in cancer and surgery. Bolstered by these results, management raised 2025 full-year guidance. The company now projects full-year reported sales of $93.2–$93.6 billion (5.1–5.6% growth) and raised its adjusted EPS outlook to $10.80–$10.90. J&J also revised tariff-related cost guidance downward after recent changes to U.S.-China trade policy, reflecting expected cost savings for the remainder of the year. Outlook: Full-year 2025 reported sales projected at $93.2–$93.6 billion. Adjusted EPS guidance lifted to $10.80–$10.90. Management expects new product approvals and expanding MedTech platforms to sustain long-term growth. Further investment and innovation are anticipated in oncology, neurology, and digital health solutions. About Inside Ticker: For more expert analysis and real-time updates on Johnson & Johnson (NYSE: JNJ) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #JohnsonAndJohnson #JNJ #Q22025 #Earnings #FinancialResults #MedTech #InnovativeMedicine #Oncology #RevenueGrowth #Darzalex #NetIncome #EPS #StockMarket #Investing #InsideTicker #Guidance #FreeCashFlow #USDollar #USMarket #InternationalGrowth #FDAApproval #Healthcare #Q2Results #BusinessUpdate #Pharmaceuticals #MedicalDevices